SAN CARLOS, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will participate in the following events in January:
25th Annual JPMorgan Healthcare Conference January 10, 2007 2:30 p.m. PT Dr. Ted W. Love, Chairman and CEO https://events.jpmorgan.com Wachovia Securities 2007 Healthcare Conference January 31, 2007 2:00 p.m. ET Dr. Ted W. Love, Chairman and CEO http://www.wsw.com/webcast/wa38/nuvo/
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed a Phase 2 clinical trial in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short- acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Foderaro, Associate Director of Corporate Communications &IR of Nuvelo, Inc., +1-650-517-8472, or nfoderaro@nuvelo.com
Web site: http://www.nuvelo.com/
